Document 2815
 DOCN  M94A2815
 TI    Lymphoproliferative responses in HIV-1-seropositive volunteers pre and
       post immunization with immuno rgp160. European Multinational Immuno AIDS
       Vaccine Study Group.
 DT    9412
 AU    Mannhalter JW; Eibl MM; Wahren B; Blazevic V; Goebel FD
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):219 (abstract no. PB0305). Unique
       Identifier : AIDSLINE ICA10/94369760
 AB    OBJECTIVE: To evaluate antigen- and mitogen-induced lymphoproliferative
       responses in two groups of HIV-1-seropositive volunteers (randomized
       according to different CD4 strata: CD4 counts > 500 and CD4 counts from
       200 to 500) pre and post immunization with the IMMUNO rgp160 AIDS
       candidate vaccine. METHODS: In a double-blind, placebo-controlled phase
       I/II study, vaccinees got 6 monthly intramuscular injections of either
       the AIDS candidate vaccine (containing 100 ug rgp160 IIIB per dose) or
       placebo (adjuvant only). One half of the volunteers received the
       vaccine, the other half placebo. At various time points pre and post
       immunization, lymphoproliferative responses to antigens (HIV-1 envelope
       proteins, tetanus toxoid, CMV antigen, alloantigens) and mitogens (PWM,
       PHA) were assessed. RESULTS: Prior to immunization with the AIDS
       candidate vaccine, rgp160-induced lymphocyte proliferation was absent or
       very low in all HIV-1-seropositive volunteers. Responses to recall
       antigens and mitogens were observed in both groups of volunteers, but
       were lower in magnitude than in HIV-1-seronegative controls.
       Proliferation in response to alloantigens was comparable in
       HIV-1-seropositive and HIV-1-seronegative subjects. Post immunization
       with the rgp160 vaccine, HIV-1 envelope-specific lymphoproliferative
       responses were found in one half of the volunteers with CD4 > 500 and in
       one third of the subjects with CD4 between 200 and 500 (note that only
       half of the volunteers received the vaccine). CONCLUSIONS: The IMMUNO
       AIDS candidate vaccine induces HIV-1 env-specific T cell memory in
       HIV-1-seropositives with CD4-pos. T cells > 500 and CD4-pos. T cells
       between 200 and 500.
 DE    Antigens/IMMUNOLOGY  AIDS Vaccines/*THERAPEUTIC USE  Gene Products,
       env/PHARMACOLOGY/*THERAPEUTIC USE  Human  HIV
       Infections/IMMUNOLOGY/*THERAPY  HIV-1/*IMMUNOLOGY  Immunization
       Immunologic Memory  *Immunotherapy, Active  *Lymphocyte
       Transformation/DRUG EFFECTS  Mitogens/PHARMACOLOGY  Protein
       Precursors/PHARMACOLOGY/*THERAPEUTIC USE  Recombinant
       Proteins/PHARMACOLOGY/THERAPEUTIC USE  T-Lymphocyte Subsets/IMMUNOLOGY
       Vaccines, Synthetic/THERAPEUTIC USE  CLINICAL TRIAL  CLINICAL TRIAL,
       PHASE I  CLINICAL TRIAL, PHASE II  MEETING ABSTRACT  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).